SAB Biotherapeutics, Inc.
SABSNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $1.3M | $2.2M | $23.9M | $60.9M | $55.2M |
| Operating income | −$49.0M | −$42.9M | −$38.1M | −$28.9M | −$13.4M | $20.6M |
| Net income | $13.3M | −$34.1M | −$42.2M | $985,863 | −$17.1M | −$8,996 |
| Total assets | $172.8M | $44.2M | $83.9M | $68.5M | $81.1M | $322,205 |
| Total liabilities | $21.3M | $18.2M | $26.6M | $27.2M | $42.6M | $17.5M |
| Equity | $151.5M | $26.0M | $57.3M | $41.3M | $38.5M | $16,004 |
| EPS (diluted) | $-0.79 | $-3.68 | $-7.64 | $-4.31 | $-0.63 | $0.74 |
| Shares out. | 9.3M | 9.2M | 50.4M | 43.0M | 14.8M | 2.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 8.8%
- Return on assets
- 7.7%
- Return on capital (ROCE)
- −30.2%
- Liabilities / assets
- 12.3%
- Debt / equity
- 0.14×
- Book value / share
- $16.31
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 6.90safe
- Accruals / assets
- 33.6%high accruals
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 2 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2023
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2021
- NT 10-Qmissed a reporting deadline ↗May 17, 2021
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2025-02-01A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo
- Phase 2Recruitingreadout ~2027-11SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.7M | 1.8 | +13.6% |
| Apr 30, 2026 | 2.4M | 6.1 | -19.4% |
| Apr 15, 2026 | 3.0M | 7.0 | +19.8% |
| Mar 31, 2026 | 2.5M | 3.0 | +28.2% |
| Mar 13, 2026 | 2.0M | 2.1 | +21.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreementMay 4, 2026
- Regulation FD disclosureApr 22, 2026
- Entered a material agreement · Other material eventMar 19, 2026
- Regulation FD disclosure · Other material eventMar 10, 2026
- Regulation FD disclosureJan 12, 2026
- Director / officer change · Regulation FD disclosureJan 7, 2026
- Other material eventDec 29, 2025
- Director / officer changeSep 30, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- 10-QMay 12, 2026
- 8-KMay 4, 2026
- SCHEDULE 13GMay 1, 2026
- DEF 14AApr 30, 2026
- 8-KApr 22, 2026
- S-8Mar 31, 2026
- 4Mar 25, 2026
- SCHEDULE 13D/AMar 23, 2026
- 8-KMar 19, 2026
- 424B5Mar 19, 2026
- 424B5Mar 17, 2026
- SCHEDULE 13D/AMar 11, 2026
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.